HIV drug resistance map: brazil study reveals why some treatments fail
NCT ID NCT07618507
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at 777 people with HIV in Brazil who failed their first treatment with tenofovir, lamivudine, and dolutegravir. Researchers wanted to understand what types of drug resistance and virus subtypes were involved. The goal is to improve treatment choices for people in Brazil and similar countries.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Tenofovir/Lamivudine and Dolutegravir
What this could lead to
If successful, this study could help doctors choose better HIV treatments for people in Brazil and similar countries by understanding which drug resistances are common.
What could go wrong
This is an observational study, not a test of a new treatment. It only looks at people who already failed therapy, so results may not apply to everyone with HIV.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centro Especializado em Doenças Infecciosas (CEDIN-DF)
Brasília, Federal District, 70351-580, Brazil
-
Centro Estadual Especializado em Diagnóstico, Assistência e Pesquisa (CEDAP)
Salvador, Estado de Bahia, 40100-160, Brazil
-
Fundação de Medicina Tropical Doutor Heitor Vieira Dourado
Manaus, Amazonas, 69040-000, Brazil
-
Hospital Nossa Senhora da Conceição
Porto Alegre, Rio Grande do Sul, 91350-200, Brazil
-
Hospital Santa Marcelina
São Paulo, São Paulo, 08270-070, Brazil
-
LADI - Laboratório de Apoio Diagnóstico em Infectologia (Hospital Universitário Miguel Riet Corrêa Jr)
Porto Alegre, Rio Grande do Sul, 90040-000, Brazil
-
Retrovirology Laboratory - UNIFESP
São Paulo, São Paulo, 04039-032, Brazil
-
Serviço Especializado em IST/HIV/AIDS Viamão
Viamão, Rio Grande do Sul, 94480-560, Brazil
-
Unidade de Infectologia William Rocha
Guarujá, São Paulo, 11471-000, Brazil